<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preferred and alternative antiretroviral regimens for nonpregnant treatment-naïve adults and adolescents with HIV-1&lt;sup&gt;¶&lt;/sup&gt;&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preferred and alternative antiretroviral regimens for nonpregnant treatment-naïve adults and adolescents with HIV-1<sup>¶</sup><sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Preferred and alternative antiretroviral regimens for nonpregnant treatment-naïve adults and adolescents with HIV-1<sup>¶</sup><sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="2"><strong>Regimen selection from the options below should be individualized based upon comorbid conditions (eg, HBV, kidney disease, osteoporosis), childbearing potential, pill burden, drug-drug interactions, and results of resistance testing.</strong></td> </tr> <tr> <td class="subtitle1_left">Preferred regimens (listed alphabetically)</td> <td class="subtitle1_left">Comments:</td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Bictegravir-emtricitabine-tenofovir alafenamide<sup>Δ</sup></li> <li>Dolutegravir plus tenofovir alafenamide-emtricitabine<sup>Δ◊</sup></li> </ul> </td> <td>For most persons with HIV who are ready to start treatment, one of these regimens can be prescribed on the same day of the confirmed diagnosis or at their initial clinic visit, even if all baseline laboratory test results haven't returned. Same-day initiation of ART has been associated with improved virologic outcomes and improved retention in care. However, a brief delay in treatment is usually indicated in patients who cannot take one of these tenofovir-based regimens (eg, patients with severely reduced kidney function) or if there is concern for certain active opportunistic infections (eg, tuberculosis, cryptococcal meningitis).</td> </tr> <tr> <td class="subtitle1_left">Alternative regimens (agents within class listed alphabetically)</td> <td class="subtitle1_left">Comments:</td> </tr> <tr> <td class="indent1"><strong>INSTI-based regimens</strong> <ul class="decimal_heading"> <li>Dolutegravir-abacavir-lamivudine</li> <li>Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide<sup>Δ◊</sup></li> <li>Raltegravir plus tenofovir alafenamide-emtricitabine<sup>Δ◊</sup></li> </ul> </td> <td> <p>Abacavir is <strong>contraindicated</strong> in patients who test positive for HLA-B*5701 and should be avoided if HLA-B*5701 testing cannot be performed.</p> Antiretroviral medications that require a boosting agent (eg, ritonavir or cobicistat) are associated with the greatest risk of drug interactions.</td> </tr> <tr> <td class="indent1"><strong>PI-based regimens</strong> <ul class="decimal_heading"> <li>Atazanavir (boosted with ritonavir or cobicistat) plus tenofovir alafenamide-emtricitabine<sup>Δ◊§</sup></li> <li>Darunavir (boosted with ritonavir or cobicistat) plus tenofovir alafenamide-emtricitabine<sup>Δ◊§¥</sup></li> </ul> </td> <td>Antiretroviral medications that require a boosting agent (eg, ritonavir or cobicistat) are associated with the greatest risk of drug interactions.</td> </tr> <tr> <td class="indent1"><strong>NNRTI-based regimens</strong> <ul class="decimal_heading"> <li>Doravirine plus tenofovir alafenamide-emtricitabine<sup>Δ◊‡</sup></li> <li>Efavirenz plus tenofovir alafenamide-emtricitabine<sup>Δ◊</sup></li> <li>Efavirenz-emtricitabine-tenofovir disoproxil fumarate<sup>◊</sup></li> <li>Rilpivirine-emtricitabine-tenofovir alafenamide<sup>Δ◊†</sup></li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1"><strong>Two-drug regimens</strong> <ul class="decimal_heading"> <li>Dolutegravir-lamivudine</li> </ul> </td> <td> <p>Data support the use of dolutegravir-lamivudine in select treatment-naïve patients who have an HIV load &lt;500,000 copies/mL, no evidence of chronic HBV infection, and no evidence of transmitted resistance to NRTIs or INSTIs (if INSTI resistance testing was obtained as part of the initial evaluation). Patients should not take concurrent medications that may significantly reduce the levels of either antiretroviral agent and should ideally have a CD4 count &gt;200 cells/microL.</p> There is less experience with other two-drug regimens (eg, boosted-darunavir plus either lamivudine or dolutegravir), and these regimens should generally be avoided.</td> </tr> </tbody></table></div><div class="graphic_lgnd">The preferred and alternative regimens listed in this table reflect our approach to the choice of antiretroviral therapy for nonpregnant treatment-naïve persons with HIV-1 and are a synthesis of guideline recommendations. This table is meant for use with UpToDate content on regimen selection in treatment-naïve patients. Additional information on the individual agents (eg, dosing, adverse events, drug interactions) can be found in the topic that provides an overview of the different antiretroviral agents as well as the Lexicomp drug monographs available within UpToDate. Antiretrovirals separated by "-" (eg, tenofovir alafenamide-emtricitabine) are available in single-tablet coformulations.</div><div class="graphic_footnotes"><p>ART: antiretroviral therapy; eGFR: estimated glomerular filtration rate; HBV: hepatitis B virus; INSTI: integrase strand transfer inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.</p>
<p>¶ Refer to the UpToDate topics that discuss HIV in pregnancy for regimens used to treat pregnant women.</p>
<p>Δ Tenofovir alafenamide-emtricitabine can be used in patients with moderately reduced kidney function (eGFR ≥30 min/mL/1.73 m<sup>2</sup>) but should be avoided in those with severely reduced kidney function not on hemodialysis.</p>
<p>◊ If tenofovir alafenamide is not available or should not be used (eg, to avoid drug interactions with rifamycins or certain antiseizure medications), tenofovir disoproxil fumarate-emtricitabine is an effective and well-tolerated choice for most patients with normal kidney function (eGFR ≥60 min/mL/1.73 m<sup>2</sup>) and for those without evidence of bone disease.</p>
<p>§ Pharmacologically boosted darunavir is better tolerated than other PIs. However, it should be used with caution in patients with sulfonamide allergy. When darunavir is used, we prefer a tenofovir-containing nucleoside combination rather than one that uses abacavir-lamivudine, as there is more experience with this regimen. If a PI is strongly desired and darunavir cannot be used, pharmacologically boosted atazanavir plus tenofovir (tenofovir alafenamide or tenofovir disoproxil fumarate)-emtricitabine can be administered.</p>
<p>¥ Darunavir is available in two coformulated tablets with cobicistat: darunavir-cobicistat and darunavir-cobicistat-emtricitabine-tenofovir alafenamide.</p>
<p>‡ Doravirine is available in a coformulated tablet with lamivudine and tenofovir disoproxil fumarate.</p>
† This regimen should be avoided in patients with a CD4 count &lt;200 cells/microL and/or an HIV RNA ≥100,000 copies/mL. In addition, it should be taken with food, and proton pump inhibitors should be avoided.</div><div class="graphic_reference">References:
<ol>
<li>Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIVs. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Available at: <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new</a> (Accessed on December 06, 2023).</li>
<li>Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA 2020; 324:1651.</li>
</ol></div><div id="graphicVersion">Graphic 130162 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
